Palavras-chave
Como Citar
Resumo
Rheumatoid arthritis (RA) is a chronic autoimmune disease that has significant unmet needs for improved treatment outcomes. This review provides an overview of emerging molecular targets and potential new therapies for managing RA. The discussed targets, such as CD40-CD40 ligand, programmed death protein 1 (PD-1), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 receptor-associated kinases (IRAKs), tyrosine kinase 2 (TYK2), bradykinin receptor 1 (B1R), and OX40-OX40 ligand, have shown promising results in preclinical studies and clinical trials. These findings stimulate continued efforts to develop more effective and safer therapeutic options, encouraging stakeholders to contribute to improving RA management.
Referências
Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Vol. 141, Advanced Drug Delivery Reviews. 2019.
Flandre TD, Mansfield KG, Espié PJ, Rubic-Schneider T, Ulrich P. Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study. Toxicol Pathol. 2022;50(5).
Chamberlain C, Colman PJ, Ranger AM, Burkly LC, Johnston GI, Otoul C, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis [Internet]. 2017 Nov 1 [cited 2024 Jun 26];76(11):1837–44. Available from: https://pubmed.ncbi.nlm.nih.gov/28780512/
Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, et al. Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS One [Internet]. 2018 Feb 1 [cited 2024 Jun 26];13(2). Available from: https://pubmed.ncbi.nlm.nih.gov/29489833/
Diab A, Abdel-Wahab N, Bentebibel SE, Montazari EJ, Spillson CA, Ekmekcioglu S, et al. 169TiP Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma. Annals of Oncology. 2021;32.
Avci AB, Feist E, Burmester GR. Targeting GM-CSF in rheumatoid arthritis. Clin Exp Rheumatol. 2016;34.
Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, et al. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol [Internet]. 2018 May 1 [cited 2024 Jun 26];70(5):679–89. Available from: https://pubmed.ncbi.nlm.nih.gov/29361199/
Buckley CD, Simón-Campos JA, Zhdan V, Becker B, Davy K, Fisheleva E, et al. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. Lancet Rheumatol [Internet]. 2020 Nov 1 [cited 2024 Jun 26];2(11):e677–88. Available from: https://pubmed.ncbi.nlm.nih.gov/38279364/
Wiese MD, Manning-Bennett AT, Abuhelwa AY. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Vol. 29, Expert Opinion on Investigational Drugs. 2020.
Kelly PN, Romero DL, Yang Y, Shaffer AL, Chaudhary D, Robinson S, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. Journal of Experimental Medicine. 2015;212(13).
Winkler A, Sun W, De S, Jiao A, Sharif MN, Symanowicz PT, et al. The IRAK4 kinase inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheumatol [Internet]. 2021 Dec 1 [cited 2024 Jun 26];73(12):2206. Available from: /pmc/articles/mid/NIHMS1734746/
Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, et al. Janus kinases to jakinibs: From basic insights to clinical practice. Rheumatology (United Kingdom). 2019;58.
Fang Z, Sun H, Wang Y, Sun Z, Yin M. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases. Biomedicine & Pharmacotherapy. 2023 Nov 1;167:115611.
Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Vol. 429, European Journal of Pharmacology. 2001.
Bas M, Greve J, Strassen U, Khosravani F, Hoffmann TK, Kojda G. Angioedema induced by cardiovascular drugs: New players join old friends. Vol. 70, Allergy: European Journal of Allergy and Clinical Immunology. 2015.
Xie Z, Dai J, Yang A, Wu Y. A role for bradykinin in the development of anti-collagen antibody-induced arthritis. Rheumatology (United Kingdom). 2014;53(7).
Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Vol. 229, Immunological Reviews. 2009.
Findlay EG, Danks L, Madden J, Cavanagh MM, McNamee K, McCann F, et al. OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci U S A. 2014;111(6).
Liu C, Yao J, Zhou X, Jin J, Zhang Z. Abstract 5178: Humanized OX40/OX40L mice as a tool for evaluating novel therapeutics. Cancer Res. 2023;83(7_Supplement).
Jiang J, Liu C, Liu M, Shen Y, Hu X, Wang Q, et al. OX40 signaling is involved in the autoactivation of CD4+CD28- T cells and contributes to the pathogenesis of autoimmune arthritis. Arthritis Res Ther. 2017 Mar 21;19(1).
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis [Internet]. 2016 Jan 1 [cited 2024 Jun 26];75(1):3–15. Available from: https://pubmed.ncbi.nlm.nih.gov/25969430/
Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, Van Der Heijde D, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6).
Thomas D, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, et al. The changing landscape of biosimilars in rheumatology. Vol. 75, Annals of the Rheumatic Diseases. 2016.
Shi P, Wang L, He J, Lu Y. Comparative Efficacy of bDMARDs and tsDMARDs for the Treatment of Rheumatoid arthritis: A Systematic Review and Network Meta-Analysis. International Journal of Biology and Life Sciences. 2023;3(1).
Prawjaeng J, Leelahavarong P, Budtarad N, Pilasant S, Chanjam C, Katchamart W, et al. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity. BMC Health Serv Res. 2023;23(1).
Kerschbaumer A, Sepriano A, Smolen JS, Van Der Heijde D, Dougados M, Van Vollenhoven R, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6).
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Francesco Maronese , Maria Laura de Biasi Alves, Juliana Coimbra de Mendonça , Afrânio Côgo Destefani , Vinícius Côgo Destefani